BNP Paribas Financial Markets
GENB

BNP Paribas Financial Markets’s Generate Biomedicines GENB Stock Holding History

BNP Paribas Financial Markets’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.1K Buy
+3,800
New +$51.8K ﹤0.01% 4772

Other funds holding GENB

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DCP
Davern Capital Partners Ny, New York $587M AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets's GENB Position: Q2 2026 in Review

BNP Paribas Financial Markets opened a new position in Generate Biomedicines (GENB) in Q2 2026: 3,800 shares worth $64.1K. The stake represents ﹤0.01% of the portfolio and ranks #4772 among its holdings.

45 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • BNP Paribas Financial Markets held 3,800 shares of Generate Biomedicines worth $64.1K as of Q2 2026.
  • Generate Biomedicines was a new BNP Paribas Financial Markets position in Q2 2026.
  • Generate Biomedicines made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4772 holding.
  • 45 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.